Anti-AKT1S1 antibody, Mouse monoclonal

AKT1S1 is a raptor-associated protein that interacts with mTORC1 and subsequently inhibits the mTORC1 signaling pathway. This raptor-binding protein also inhibits phosphorylation of S6K1 and cell growth. Expression of AKT1S1 has been implicated in breast and pulmonary carcinogenesis, as well as in mediating insulin sensitivity . Monoclonal Anti-AKT1S1 antibody is specific for human AKT1S1 (approx. 40 kDa).

Monoclonal Anti-AKT1S1 (mouse IgG1 isotype) is derived from the hybridoma AKT1S1-3 produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with a fusion protein corresponding to the N-terminus of human AKT1S1. Akt1 substrate 1 (AKT1S1) is also named as proline-rich Akt-substrate of 40 kDa (PRAS40). The rapamycin-sensitive mammalian target of rapamycin complex 1 (mTORC1) consists of mTOR, raptor, mLST8 and AKT1S1, that controls protein translation. AKT1S1 contains a TOR signaling (TOS) motif that mediates its binding to mTORC1.

The corresponding sequence differs by a single amino acid in rat, and by 2 amino acids in mouse AKT1S1.

fusion protein corresponding to the N-terminus of human AKT1S1.

Monoclonal Anti-AKT1S1 antibody is suitable for use in western blot (2-8 μg/mL using whole extracts of human MDA-MB-231cells) and immunoprecipitation.

Akt1 substrate 1 (AKT1S1) is involved in the PI3KAkt/ protein kinase B (PKB) survival pathway. Phosphorylation of AKT1S1 by Akt and mammalian target of rapamycin complex 1 (mTORC1) disrupts the binding between mTORC1 and AKT1S1, relieves the inhibitory effect of AKT1S1 on mTORC1 activity, and leads to the binding of AKT1S1 to 14-3-3, a cytosolic anchor protein. The binding of AKT1S1 to 14-3-3 requires amino acids and insulin, which is partially inhibited by rapamycin.

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.